Merck and Moderna Melanoma Vaccine Trial Succeeded

The firms met primary endpoints in a Phase 3 study of their personalized mRNA treatment for high-risk melanoma patients.

Updated on Oct. 12, 2026 in Cancer

Merck and Moderna Melanoma Vaccine Trial Succeeded

Live Poll

Do you trust that new personalized medical treatments will remain affordable for your household?

Merck and Moderna have reached primary endpoints in the Phase 3 INTerpath-001 trial for their personalized mRNA melanoma vaccine, intismeran autogene. The treatment, which is designed to be paired with Keytruda, requires a tumor biopsy and genetic sequencing for each patient.

Why it matters

This milestone validates the potential of individualized cancer vaccines that are custom-engineered for specific patients. While the melanoma trial showed promise, BioNTech and Genentech recently discontinued a separate trial for colorectal cancer, highlighting the varying success of these treatments across different cancer types.

The therapy encodes up to 34 patient-specific neoantigens, with the industry targeting a six to eight week turnaround from initial biopsy to the delivery of the first dose. Manufacturing costs currently represent 77% of the total selling price for these personalized batches.

The players

Merck

A multinational pharmaceutical company known for developing oncology therapies including Keytruda.

Moderna

A biotechnology company specializing in mRNA-based medicine and clinical-scale vaccine manufacturing.

BioNTech

A German biotechnology firm focused on patient-specific immunotherapies for the treatment of cancer.

Genentech

A biotechnology corporation that conducts research and development on complex oncological treatments.

The details

Production involves n-of-1 manufacturing to create many small, customized batches at Moderna’s Marlborough, Massachusetts, facility. Each vaccine is uniquely coded to the genetic profile of a patient’s tumor to stimulate a specific immune reaction.

September 2025: Moderna began supplying clinical vaccine batches from its facility in Massachusetts.

Health Landscape

This development represents a major technical advancement in personalized medicine following the historical precedent set by the launch of Provenge. It highlights the shifting success rates of mRNA treatments as manufacturers move toward n-of-1 production models.

Patients may eventually see a new treatment option for melanoma that integrates personalized genetic sequencing into their immunotherapy regimen. However, the high manufacturing cost and the six-to-eight-week production window for custom vaccines may limit immediate access upon approval.

The takeaway

Personalized mRNA treatments require significant lead time for genetic analysis and custom production per patient. Patients should consult with oncologists to determine if current trials or future therapies align with their specific cancer profile.